Tekmira Announces Election of Directors VANCOUVER, British Columbia, May 17, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced that the nominees listed in the management proxy circular for the 2013 Annual and Special Meeting of Shareholders were elected as directors of Tekmira at the annual meeting held on May 14, 2013 in Vancouver. Detailed results of the vote for the election of directors are set out below: Nominee Votes For % For Votes Withheld % Withheld Michael Abrams 1,944,876 99.25% 14,740 0.75% Kenneth Galbraith 1,945,046 99.26% 14,570 0.74% Don Jewell 1,945,116 99.26% 14,500 0.74% Frank Karbe 1,942,816 99.14% 16,800 0.86% Daniel Kisner 1,943,276 99.17% 16,340 0.83% Mark J. Murray 1,942,146 99.11% 17,470 0.89% About Tekmira Tekmira Pharmaceuticals Corporation is a biopharmaceutical company focused on advancing novel RNAi therapeutics and providing its leading lipid nanoparticle delivery technology to pharmaceutical partners. Tekmira has been working in the field of nucleic acid delivery for over a decade and has broad intellectual property covering LNPs. Further information about Tekmira can be found at www.tekmirapharm.com. Tekmira is based in Vancouver, B.C. CONTACT: Investors Jodi Regts Director, Investor Relations Phone: 604-419-3234 Email: firstname.lastname@example.org Media David Ryan Longview Communications Inc. Phone: 416-649-8007 Email: email@example.com Tekmira Pharmaceuticals Logo
Tekmira Announces Election of Directors
Press spacebar to pause and continue. Press esc to stop.